Should We Reintroduce Previous Venous Thromboembolism Into Decision-Making for Anticoagulation in Atrial

Thure Filskov Overvad1, Flemming Skjøth2, Ida Ehlers Albertsen3

  • 1Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Faculty of Health, Aalborg University, Denmark; Department of Medicine, North Denmark Regional Hospital, Hjørring, Denmark.

Insights

History of venous thromboembolism (VTE) did not increase stroke risk in atrial fibrillation patients. However, a prior VTE history indicates a higher overall risk for future thromboembolic events, including VTE itself.

Area of Science:

  • Cardiology
  • Hematology
  • Epidemiology

Background:

  • Atrial fibrillation (AF) is a major risk factor for thromboembolic events.
  • The prognostic significance of a prior history of venous thromboembolism (VTE) in AF patients remains unclear.

Purpose of the Study:

  • To determine if a history of VTE impacts the risk of future thromboembolic events in patients diagnosed with atrial fibrillation.

Main Methods:

  • Nationwide cohort study (2000-2017) using Danish health registries.
  • Included 246,313 patients with incident atrial fibrillation.
  • Cox regression analyses adjusted for CHA₂DS₂-VASc score components and oral anticoagulation use.

Main Results:

  • Patients with prior VTE had a similar adjusted risk for ischemic stroke or systemic embolism (HR 0.99; 95% CI, 0.90-1.09).
  • Patients with prior VTE faced a significantly higher risk for a composite outcome including VTE (HR 1.76; 95% CI, 1.64-1.90).
  • Findings were consistent across VTE subtypes, low CHA₂DS₂-VASc scores, and non-anticoagulated patients.

Conclusions:

  • Prior VTE history does not elevate stroke risk in AF patients.
  • Individuals with AF and prior VTE represent a high-risk group due to increased risk of future VTE.
  • This risk stratification is crucial for oral anticoagulation decision-making in AF patients.
Abstract

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
191
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.4K
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
177
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.8K
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
138
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
196